FindTrial
Sign In

Use of clembuterol in patients affected by valvular hearth disease and dilated cardiomyopathy - ND

Use of clembuterol in patients affected by valvular hearth disease and dilated cardiomyopathy - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-001889-16-IT
Enrollment
Unknown
Registered
2007-07-25
Start date
2006-03-01
Completion date
Unknown
Last updated
2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No healthy subjects (patients affected by valvular hearth disease and dilated cardiomyopathy) MedDRA version: 9.1 Level: LLT Classification code 10024119 Term: Left ventricular failure

Interventions

Trade Name: SPIROPENT*30CPR 0,02MG Pharmaceutical Form: Tablet INN or Proposed INN: Clenbuterol CAS Number: 21898-19-1 Concentration unit: µg microgram(s) Concentration type: equal Concentration numbe

Sponsors

AZIENDA OSPEDALIERA SENESE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: o NYHA functional class ≥ III o Ejection fraction (EF) ≤ 35% o (LVEDD) ≥ 55 o Subscription of Informed consensus. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Allergy to any of medication included in the protocol. Ipersensitivity to simpatic amine pregnant women

Design outcomes

Primary

MeasureTime frame
Main Objective: Evaluation of possible functional improvement expressed by improved hearth contractility and reverse remodeling;Secondary Objective: None;Primary end point(s): Verify doping effect of the combined therapy—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026